Immunogenicity Study of Abbreviated Rabies Preexposure Vaccination Schedules: Table 1

Khawplod, Pakamatz; Wilde, Henry; Benjavongkulchai, Maneerat; Sriaroon, Chakrapol; Chomchey, Pranee

doi:10.1111/j.1708-8305.2007.00120.x

Cited by 44 publications

(35 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In one of the study arms, Khawplod and coworkers administered two ID doses at two sites on a single visit as primary vaccination, using PCECV or PVRV. Upon two ID booster doses (Day 0 and 3) one year later, all subjects elicited anamnestic immune responses and adequate RVNA concentrations [19]. …”

Section: Discussionmentioning

confidence: 99%

Immunogenicity of Simulated PCECV Postexposure Booster Doses 1, 3, and 5 Years after 2-Dose and 3-Dose Primary Rabies Vaccination in Schoolchildren

Kamoltham

Thinyounyong

Khawplod

et al. 2011

Advances in Preventive Medicine

Self Cite

View full text Add to dashboard Cite

Objectives. To assess the immunogenicity of intradermal (ID) booster doses of Purified Chick Embryo Cell rabies vaccine (PCECV, Rabipur) administered to Thai schoolchildren one, three and five years after a primary ID pre-exposure (PrEP) vaccination series. Methods. In this follow-up study of a randomized, open-label, phase II clinical trial, two simulated post-exposure booster doses of PCECV were administered on days 0 and 3 intradermally to 703 healthy schoolchildren, one, three or five years after primary vaccination with either two or three ID doses of 0.1 mL PCECV. Blood was drawn immediately before and 7, 14 and 365 days after the first booster dose to determine rabies virus neutralizing antibody (RVNA) concentrations. Results. An anamnestic response of approximately 30-fold increase in RVNA concentrations was demonstrated within 14 days after booster. All children (100%) developed adequate RVNA concentrations above 0.5 IU/mL. No vaccine related serious adverse events were seen in any of the vaccinees. Conclusion. ID rabies PrEP with PCECV is safe and immunogenic in schoolchildren and the anamnestic response to a two booster dose vaccination series was found to be adequate one, three, and five years after a two- or three-dose primary PrEP vaccination series.

show abstract

Section: Discussionmentioning

confidence: 99%

Immunogenicity of Simulated PCECV Postexposure Booster Doses 1, 3, and 5 Years after 2-Dose and 3-Dose Primary Rabies Vaccination in Schoolchildren

Kamoltham

Thinyounyong

Khawplod

et al. 2011

Advances in Preventive Medicine

Self Cite

View full text Add to dashboard Cite

show abstract

“…There were 11 citations identified that reported immunogenicity data following ID PVRV for PrEP [16,[20][21][22][23][24][25][26][27][28][29]; of these, 6 were undertaken in Thailand [20,23,25,[28][29][30]. The other studies were undertaken in Vietnam [24,27] (both these Vietnamese studies reported data on the same cohort of children), Brazil [22], and The Netherlands [16,21].…”

Section: Immunogenicity Of Prep Regimensmentioning

confidence: 99%

“…Seroconversion rates from day 14 to 56 after the first vaccination and at 1 year across the studies identified were 90-100% and 20-96%, respectively [16,[21][22][23]25,[27][28][29]. The RVNA GMTs reported across the studies irrespective of PrEP regimen (n = 926), including following booster vaccination after one year, are summarized in Figure 2 [16,[20][21][22][23][24][25][26][27][28][29].…”

Section: Immunogenicity Up To 1 Yearmentioning

confidence: 99%

Purified Vero Cell Rabies Vaccine (PVRV, Verorab®): A Systematic Review of Intradermal Use Between 1985 and 2019

et al. 2020

View full text Add to dashboard Cite

The purified Vero cell rabies vaccine (PVRV; Verorab ® , Sanofi Pasteur) has been used in rabies prevention since 1985. Evolving rabies vaccination trends, including shorter intradermal (ID) regimens with reduced volume, along with WHO recommendation for ID administration has driven recent ID PVRV regimen assessments. Thus, a consolidated review comparing immunogenicity of PVRV ID regimens during pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) is timely and beneficial in identifying gaps in current research. A search of seven databases for studies published from 1985 to November 2019 identified 35 studies. PrEP was assessed in 10 studies (n = 926) with 1-3-site, 1-3-visit regimens of up to 3-months duration. Seroconversion (rabies virus neutralizing antibodies [RVNA] ≥ 0.5 IU/mL) rates of 90-100% were reported within weeks, irrespective of regimen, with robust booster responses at 1 year (100% seroconversion rates by day 14 post-booster). However, data are lacking for the current WHO-recommended, 2-site, 1-week ID PrEP regimen. PEP was assessed in 25 studies (n = 2136) across regimens of 1-week to 90-day duration. All ID PEP regimens assessed induced ≥ 99% seroconversion rates (except in HIV participants) by day 14-28. This review confirms ID PVRV suitability for rabies prophylaxis and highlights the heterogeneity of use in the field.

show abstract

“…Previous studies utilizing the PCEC-K intradermal regimen reported that, 6 months after immunization, approximately half the subjects had reduced NA titers below 0.5 IU/ml and responded well to booster vaccination [5]. Khawplod et al [11] have also shown that an intradermal booster dose achieved significant NA titers. It is strongly suggested by our data that a 0.1-ml booster inoculation of PCEC-K will produce protective titers, making the intradermal protocol a putative candidate for booster vaccination.…”

Section: Discussionmentioning

confidence: 96%

Immunogenicity of intradermal vaccination of Japanese rabies vaccine for preexposure immunization following WHO recommendation

Yanagisawa

Takayama

Mannen

et al. 2012

Journal of Infection and Chemotherapy

View full text Add to dashboard Cite

Immunogenicity Study of Abbreviated Rabies Preexposure Vaccination Schedules: Table 1

Abstract: It might be possible to develop a 1-week and even one clinic visit preexposure vaccine schedule that would provide at least 1 year of immune memory.

Cited by 44 publications

References 6 publications

Immunogenicity of Simulated PCECV Postexposure Booster Doses 1, 3, and 5 Years after 2-Dose and 3-Dose Primary Rabies Vaccination in Schoolchildren

Immunogenicity of Simulated PCECV Postexposure Booster Doses 1, 3, and 5 Years after 2-Dose and 3-Dose Primary Rabies Vaccination in Schoolchildren

Purified Vero Cell Rabies Vaccine (PVRV, Verorab®): A Systematic Review of Intradermal Use Between 1985 and 2019

Immunogenicity of intradermal vaccination of Japanese rabies vaccine for preexposure immunization following WHO recommendation

Contact Info

Product

Resources

About